BioCentury | Mar 16, 2018
Financial News

AI play BioXcel raises $60M IPO

...to identify new indications for approved or clinically validated products. An IV formulation of BioXcel's BXCL501...
BioCentury | Mar 8, 2018
Financial News

AI play BioXcel raises $60M IPO

...to identify new indications for approved or clinically validated products. An IV formulation of BioXcel's BXCL501...
...cancer. The biotech plans to move both programs into Phase II proof-of-concept studies this year. Sandi Wong BXCL501 BXCL701 BioXcel...
BioCentury | May 19, 2017
Company News

BioXcel creates subsidiary to develop cancer, neurology candidates

...combination with immune-checkpoint inhibitors to treat castration resistant prostate cancer (CRPC) and other cancers; and BXCL501...
...trial for BXCL701 and a proof-of-concept trial for the BXCL501. It will pursue approval for BXCL501...
...Inc. , which ceased operations in 2007. BioXcel Corp. , Branford, Conn. Business: Cancer, Neurology Julian Zhu BXCL501 BXCL701 BXCL702 BioXcel...
Items per page:
1 - 3 of 3